Nicholas J Neill
Overview
Explore the profile of Nicholas J Neill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
795
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henke D, Renwick A, Zoeller J, Meena J, Neill N, Bowling E, et al.
NPJ Precis Oncol
. 2025 Feb;
9(1):39.
PMID: 39915634
Precision medicine relies on identifying reliable biomarkers for gene dependencies to tailor individualized therapeutic strategies. The advent of high-throughput technologies presents unprecedented opportunities to explore molecular disease mechanisms but also...
2.
Meena J, Wang J, Neill N, Keough D, Putluri N, Katsonis P, et al.
Cancer Discov
. 2024 Aug;
14(9):1699-1716.
PMID: 39193992
Upregulation of MYC is a hallmark of cancer, wherein MYC drives oncogenic gene expression and elevates total RNA synthesis across cancer cell transcriptomes. Although this transcriptional anabolism fuels cancer growth...
3.
Einstein J, Perelis M, Chaim I, Meena J, Nussbacher J, Tankka A, et al.
Mol Cell
. 2021 Jul;
81(15):3048-3064.e9.
PMID: 34216543
RNA-binding proteins (RBPs) are critical regulators of post-transcriptional gene expression, and aberrant RBP-RNA interactions can promote cancer progression. Here, we interrogate the function of RBPs in cancer using pooled CRISPR-Cas9...
4.
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling E, Wang J, Gong F, Wu W, Neill N, Kim I, et al.
Cell
. 2021 Jan;
184(2):384-403.e21.
PMID: 33450205
Many oncogenic insults deregulate RNA splicing, often leading to hypersensitivity of tumors to spliceosome-targeted therapies (STTs). However, the mechanisms by which STTs selectively kill cancers remain largely unknown. Herein, we...
5.
Lu H, Villafane N, Dogruluk T, Grzeskowiak C, Kong K, Tsang Y, et al.
Cancer Res
. 2017 May;
77(13):3502-3512.
PMID: 28512244
Oncogenic gene fusions drive many human cancers, but tools to more quickly unravel their functional contributions are needed. Here we describe methodology permitting fusion gene construction for functional evaluation. Using...
6.
Hsu T, Simon L, Neill N, Marcotte R, Sayad A, Bland C, et al.
Nature
. 2015 Sep;
525(7569):384-8.
PMID: 26331541
MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC...
7.
Rosenfeld J, Fox J, Descartes M, Brewer F, Stroud T, Gorski J, et al.
Am J Med Genet A
. 2015 Mar;
167A(2):345-53.
PMID: 25756153
Uniparental disomy (UPD) for imprinted chromosomes can cause abnormal phenotypes due to absent or overexpression of imprinted genes. UPD(14)pat causes a unique constellation of features including thoracic skeletal anomalies, polyhydramnios,...
8.
Carvalho C, Zuccherato L, Williams C, Neill N, Murdock D, Bainbridge M, et al.
BMC Med Genet
. 2014 Jun;
15:64.
PMID: 24898207
Background: Shwachman-Diamond syndrome (SDS) is an autosomal recessive ribosomopathy caused mainly by compound heterozygous mutations in SBDS. Structural variation (SV) involving the SBDS locus has been rarely reported in association...
9.
Shuvarikov A, Campbell I, Dittwald P, Neill N, Bialer M, Moore C, et al.
Hum Mutat
. 2013 Jul;
34(10):1415-23.
PMID: 23878096
We describe the molecular and clinical characterization of nine individuals with recurrent, 3.4-Mb, de novo deletions of 3q13.2-q13.31 detected by chromosomal microarray analysis. All individuals have hypotonia and language and...
10.
Dabell M, Rosenfeld J, Bader P, Escobar L, El-Khechen D, Vallee S, et al.
Am J Med Genet A
. 2013 Mar;
161A(4):717-31.
PMID: 23495017
Deletions at 2p16.3 involving exons of NRXN1 are associated with susceptibility for autism and schizophrenia, and similar deletions have been identified in individuals with developmental delay and dysmorphic features. We...